141 related articles for article (PubMed ID: 16518967)
21. Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats.
Liu RY; Wu LZ; Huang BJ; Huang JL; Zhang YL; Ke ML; Wang JM; Tan WP; Zhang RH; Chen HK; Zeng YX; Huang W
Virus Res; 2005 Sep; 112(1-2):24-31. PubMed ID: 16022898
[TBL] [Abstract][Full Text] [Related]
22. Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins.
Tripp RA; Haynes LM; Moore D; Anderson B; Tamin A; Harcourt BH; Jones LP; Yilla M; Babcock GJ; Greenough T; Ambrosino DM; Alvarez R; Callaway J; Cavitt S; Kamrud K; Alterson H; Smith J; Harcourt JL; Miao C; Razdan R; Comer JA; Rollin PE; Ksiazek TG; Sanchez A; Rota PA; Bellini WJ; Anderson LJ
J Virol Methods; 2005 Sep; 128(1-2):21-8. PubMed ID: 15885812
[TBL] [Abstract][Full Text] [Related]
23. Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology.
Berry JD; Hay K; Rini JM; Yu M; Wang L; Plummer FA; Corbett CR; Andonov A
MAbs; 2010; 2(1):53-66. PubMed ID: 20168090
[TBL] [Abstract][Full Text] [Related]
24. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.
He Y; Zhu Q; Liu S; Zhou Y; Yang B; Li J; Jiang S
Virology; 2005 Mar; 334(1):74-82. PubMed ID: 15749124
[TBL] [Abstract][Full Text] [Related]
25. B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein.
Zhong X; Yang H; Guo ZF; Sin WY; Chen W; Xu J; Fu L; Wu J; Mak CK; Cheng CS; Yang Y; Cao S; Wong TY; Lai ST; Xie Y; Guo Z
J Virol; 2005 Mar; 79(6):3401-8. PubMed ID: 15731234
[TBL] [Abstract][Full Text] [Related]
26. Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus.
Berry JD; Jones S; Drebot MA; Andonov A; Sabara M; Yuan XY; Weingartl H; Fernando L; Marszal P; Gren J; Nicolas B; Andonova M; Ranada F; Gubbins MJ; Ball TB; Kitching P; Li Y; Kabani A; Plummer F
J Virol Methods; 2004 Sep; 120(1):87-96. PubMed ID: 15234813
[TBL] [Abstract][Full Text] [Related]
27. Template-based coiled-coil antigens elicit neutralizing antibodies to the SARS-coronavirus.
Tripet B; Kao DJ; Jeffers SA; Holmes KV; Hodges RS
J Struct Biol; 2006 Aug; 155(2):176-94. PubMed ID: 16697221
[TBL] [Abstract][Full Text] [Related]
28. Identification and antigenic epitope mapping of immunodominant region amino residues 510 to 672 on the spike protein of the severe acute respiratory syndrome coronavirus.
Hua RH; Wang YF; Bu ZG; Zhou YJ; Ge JY; Wang XJ; Tong GZ
DNA Cell Biol; 2005 Aug; 24(8):503-9. PubMed ID: 16101348
[TBL] [Abstract][Full Text] [Related]
29. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice.
Greenough TC; Babcock GJ; Roberts A; Hernandez HJ; Thomas WD; Coccia JA; Graziano RF; Srinivasan M; Lowy I; Finberg RW; Subbarao K; Vogel L; Somasundaran M; Luzuriaga K; Sullivan JL; Ambrosino DM
J Infect Dis; 2005 Feb; 191(4):507-14. PubMed ID: 15655773
[TBL] [Abstract][Full Text] [Related]
30. Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse.
Coughlin M; Lou G; Martinez O; Masterman SK; Olsen OA; Moksa AA; Farzan M; Babcook JS; Prabhakar BS
Virology; 2007 Apr; 361(1):93-102. PubMed ID: 17161858
[TBL] [Abstract][Full Text] [Related]
31. Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents.
Keng CT; Zhang A; Shen S; Lip KM; Fielding BC; Tan TH; Chou CF; Loh CB; Wang S; Fu J; Yang X; Lim SG; Hong W; Tan YJ
J Virol; 2005 Mar; 79(6):3289-96. PubMed ID: 15731223
[TBL] [Abstract][Full Text] [Related]
32. Conserved amino acids W423 and N424 in receptor-binding domain of SARS-CoV are potential targets for therapeutic monoclonal antibody.
Bian C; Zhang X; Cai X; Zhang L; Chen Z; Zha Y; Xu Y; Xu K; Lu W; Yan L; Yuan J; Feng J; Hao P; Wang Q; Zhao G; Liu G; Zhu X; Shen H; Zheng B; Shen B; Sun B
Virology; 2009 Jan; 383(1):39-46. PubMed ID: 18986662
[TBL] [Abstract][Full Text] [Related]
33. Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV).
Suresh MR; Bhatnagar PK; Das D
J Pharm Pharm Sci; 2008 Apr; 11(2):1s-13s. PubMed ID: 19203466
[TBL] [Abstract][Full Text] [Related]
34. [Potent neutralization antibody elicited in mice by SARS-associated coronavirus spike protein S1 domain].
Zhang Y; Yang F; Li YH; Li WH; Tu XM; Wei Q; Zhu H; Liu L; Wang H; Qin C; Yuan GY; He W; Wang SH
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Sep; 18(3):258-60. PubMed ID: 15640862
[TBL] [Abstract][Full Text] [Related]
35. Quantitative comparison of the efficiency of antibodies against S1 and S2 subunit of SARS coronavirus spike protein in virus neutralization and blocking of receptor binding: implications for the functional roles of S2 subunit.
Zeng F; Hon CC; Yip CW; Law KM; Yeung YS; Chan KH; Malik Peiris JS; Leung FC
FEBS Lett; 2006 Oct; 580(24):5612-20. PubMed ID: 16989815
[TBL] [Abstract][Full Text] [Related]
36. Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein.
Zhi Y; Kobinger GP; Jordan H; Suchma K; Weiss SR; Shen H; Schumer G; Gao G; Boyer JL; Crystal RG; Wilson JM
Virology; 2005 Apr; 335(1):34-45. PubMed ID: 15823604
[TBL] [Abstract][Full Text] [Related]
37. Generation of human antibody fragments recognizing distinct epitopes of the nucleocapsid (N) SARS-CoV protein using a phage display approach.
Flego M; Di Bonito P; Ascione A; Zamboni S; Carattoli A; Grasso F; Cassone A; Cianfriglia M
BMC Infect Dis; 2005 Sep; 5():73. PubMed ID: 16171519
[TBL] [Abstract][Full Text] [Related]
38. A chimeric multi-epitope DNA vaccine elicited specific antibody response against severe acute respiratory syndrome-associated coronavirus which attenuated the virulence of SARS-CoV in vitro.
Wang X; Xu W; Tong D; Ni J; Gao H; Wang Y; Chu Y; Li P; Yang X; Xiong S
Immunol Lett; 2008 Aug; 119(1-2):71-7. PubMed ID: 18533276
[TBL] [Abstract][Full Text] [Related]
39. [Immunological reaction between the peptides from S1 domain of SARS coronavirus S-protein and the serum from SARS patients].
Zhang JJ; Wu SY; Xu W; Hou JL; Wang ZH; Jiang SB; Wu SG
Di Yi Jun Yi Da Xue Xue Bao; 2004 Jul; 24(7):789-90, 797. PubMed ID: 15257904
[TBL] [Abstract][Full Text] [Related]
40. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.
Chen Z; Zhang L; Qin C; Ba L; Yi CE; Zhang F; Wei Q; He T; Yu W; Yu J; Gao H; Tu X; Gettie A; Farzan M; Yuen KY; Ho DD
J Virol; 2005 Mar; 79(5):2678-88. PubMed ID: 15708987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
